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Studies have suggested that there is a higher prevalence of asthma in northern Sweden than in southern Sweden. 
Bronchial hyper-responsiveness (BHR) has been shown to be associated with asthma. The aim of this study was to 
explore the prevalence of bronchical hyper-responsiveness in different parts of Sweden. 
As part of the European Community Respiratory Health Survey (ECRHS), interviews, skin prick tests, lung 
function tests and methacholine provocation tests of the airways were performed in 1448 randomly selected subjects 
in southern, central and northern Sweden. The Mefar dosimeter was used according to the ECRHS protocol. The 
responsiveness was calculated both as the PD,, and as the dose response slope (DRS). BHR was defined as a PD,, 
of I 1.6 mg. Atopy was defined as at least one skin prick test of 2 3 mm. 
The prevalence of BHR was 12.7%, 10.6% in men and 15.0% in women. No difference in prevalence was found 
between the three different regions of Sweden. The prevalence of BHR was higher in women than in men and higher 
in smokers than in non-smokers. Using multiple logistic regression, with BHR as the dependent variable, atopy, 
being female, having a low FEV, (% predicted) and smoking (both own and passive) increased the odds of having 
BHR, while age and the region of Sweden did not influence BHR. Defining BHR as a PD,, of 5 I.0 mg or a PD,, 
of 12.0 mg did not change this. Multiple regression using log DRS as the dependent variable produced the same 
result. Both BHR and increasing DRS were associated with self-reported wheezing, attacks of shortness of breath 
during the daytime at rest or after strenuous activity, being awakened by a feeling of tightness in the chest or an 
attack of shortness of breath. In subjects without self-reported asthma, BHR was associated with self-reported 
wheezing and attacks of shortness of breath after strenuous activity. 
In conclusion, we found that the prevalence of BHR in the three investigated areas was 12.7%. We found a trend 
towards.a higher prevalence of BHR in the most northerly of the study areas, but the difference between the areas 
was not statistically significant. BHR and DRS were associated with atopy, smoking, female sex and FEV, 
(%predicted). The reporting of symptoms from the airways was associated with the degree of bronchical 
responsiveness. 
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Introduction 
Studies in Sweden have suggested that the prevalence of 
asthma is higher in the northern part of the country than in 
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the southern part (l-6). However, no study of adults has 
been performed using the same methodology at the same 
time in different parts of the country. No previous studies 
of the prevalence of bronchical hyper-responsiveness 
(BHR) over the country as a whole have been conducted. 
Non-specific airway responsiveness has been measured in 
several population-based studies (7-24). Many studies have 
found that there is an elevated prevalence of BHR in 
asthmatics compared with non-asthmatics (7,8,12,18-24). 
However, BHR has also been shown to occur in 
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asymptomatic subjects and in subjects with other airway 
diseases, such as COPD, sarcoidosis, bronchiectasies and 
cystic fibrosis (10,25,26). Furthermore, there appears to be 
an association between atopy and BHR (7-9,12,13,15, 
20,22,23). In subjects sensitized to birch pollen with no 
known asthma, increased reactivity has been shown to 
occur during and immediately after the pollen season (27). 
Smoking and low FEV, (% predicted) have also been 
shown to be associated with BHR (8-10,17,20,22,23,25). 
Another factor which has been shown to increase the 
prevalence of BHR is the inhalation of cold air. Top-class 
cross-country skiers have been shown to have a high 
prevalence of BHR (28). 
The pathological relevance of BHR is non-symptomatic 
subjects is unclear. In asymptomatic children, BHR has 
been shown to be risk factor for asthma (12,18,19). How- 
ever, there is some evidence that the awareness of symptoms 
(of airway obstruction) might differ between individuals 
with BHR and known asthma and individuals with BHR 
and no known asthma (11). 
As part of the European Community Respiratory Health 
Survey (ECRHS), non-specific airway responsiveness was 
assessed in 1448 randomly selected subjects from three 
different parts of Sweden. The main aims of this study were 
to estimate the prevalence of BHR in Sweden and to 
determine whether the prevalence of non-specific airway 
responsiveness differs between different parts of the 
country. The impact of some known risk factors on BHR 
was also examined. 
Material and Method 
STUDY POPULATION 
The ECRHS is a multinational survey with the aim of 
estimating the prevalence of asthma-like symptoms, atopy 
and bronchial lability. The survey also studies exposure to 
suspected risk factors and the treatment of asthma. 
Forty-eight centres participate, each with a defined 
study area in terms of geographical and administrative 
boundaries. In Sweden, three such centres participate: 
Giiteborg (Hisingen), Uppsala and a part of the county of 
Vasterbotten (UmeCLycksele health care districts). 
In the first part of the study, a postal questionnaire was 
sent out to 1800 men and 1800 women at each centre. The 
subjects were randomly selected from the county council 
population register in the three areas. The questionnaire 
was the ECRHS modified version of the IUATLD ques- 
tionnaire (29). In addition, five questions on bronchitis- 
related symptoms and smoking habits from a Swedish 
questionnaire, validated against clinical examination (4) 
were added to the Swedish questionnaire. The results of this 
part of the study have already been published (30). 
In the second part of the study, 950 subjects in Goteborg, 
800 in Uppsala and 672 in Vasterbotten were randomly 
selected from the initial sample (Fig. 1). The different 
numbers were due to differences in estimated participation 
rates between the centres. The aim was to obtain a sub- 
sample of 600 subjects from each centre. Only those who 
had previously responded to the screening questionnaire 
were invited to participate (772 from Giiteborg, 707 from 
Uppsala and 605 from Vbterbotten). The second part of 
the study consisted of an interview, a lung function test, 
a skin prick test, a blood sample and a methacholine 
challenge. This second part of the study was carried out 
between February 1991 and June 1992. The study was 
approved of by the three local ethics committees and by the 
Swedish Data Protection Board. 
STUDY AREAS 
Goteborg is Sweden’s second largest city. This study area 
comprised the northern part of the city on the island of 
Hisingen. In this area, there was a large number of immi- 
grants. The winters here are milder than in the other two 
areas. The annual income per inhabitant was lower than at 
the other two centres. Mean temperature in 1990 was 9.6”C. 
Uppsala is a medium-sized university city, with par- 
ticipants from both the inner city and the surrounding 
countryside. The temperature is moderate. Industrial pollu- 
tion is low. Mean temperature in 1990 was 7.2”C. 
Vhterbotten [Umea-Lycksele health care districts 
(southern and western parts of the county of Vasterbotten)] 
is a region with both urban and rural areas. The climate is 
subarctic and industrial pollution is low. In winter, during 
occasional periods of thermal inversion, high levels of soot 
from wood stoves and other sources of combustion may 
occur locally. Mean temperature in 1990 was 4.5”C. 
METHODS 
The study protocol was the ECRHS protocol (29). A short 
description is given below. 
Interview 
The interviews were carried out by nurses, trained in 
interviewing. The ECRHS interview protocol had been 
translated into Swedish and retranslated to minimize 
language bias. 
Skin Prick Test 
Phazet (Pharmacia) was used. The tests were carried out by 
specially trained nurses. The ECRHS test protocol was 
used, but two local allergens, mugwort and dog, were added 
to the standard protocol panel. A reaction was regarded as 
positive if the mean diameter of the resulting wheal was 
2 3 mm larger than that of the negative control. Atopy was 
defined as at least one positive skin prick test. 
Lung Function Test 
FEV, and VC were measured following the protocol of the 
ECRHS. The Spiro Medics computerized dry-rolling seal 
spirometer system 2130 (Sensor Medics, Anaheim, CA, 
U.S.A.) was used. The best values from five trials were 
chosen. FEV, (% predicted) was calculated using the nor- 
mal values of the European Coal and Steel Community (3 1). 
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Stage 1, random sample 
Answered questionnaire 
Percentage 
Stage 2, random 
subsample 
Invited to &ge 2 
(random subsample + 
answered stage 1) 
Participated in stage 2, 
Percentage of invited 
Percentage of subsample 
Participated in methacholine test 
Percentage of invited 
Total 
n = 10 800 
i 
n = 9281 
86% 
I 
n=2422 
I 
n=2084 
I 
n = 1859 
89% 
77% 
1 
n = 1448 
78% 
G6teborg 
3600 
I I 1 I I 
i 
2885 
80% 
I 
950 
I 
172 
I 
682 
88% 
72% 
I 
538 
79% 
Uppsala Vksterbotten 
3600 3600 
I I I I 1 1 I I I I 
i i 
3144 3252 
87% 90% 
I I 
800 672 
I i 
701 605 
I i 
625 552 
88% 91% 
78% 82% 
: I 
499 411 
80% 75% 
FIG. 1. Participation in methacholine challenge test. 
Methacholine Challenge Test 
The tests were performed using the ECRHS protocol for 
methacholine challenge. The Mefar MB3 dosimeter (Mefar 
Ele H20, Medicali, Brescia, Italy) was used. It was cali- 
brated to deliver 0.01 ml of aerosol to the mouth, with an 
inhalation time of 1 s. Each dose was delivered during a 
slow inspiratory manoeuvre from functional residual capac- 
ity to total lung capacity. The subjects were asked to hold 
their breath for 3 s after each inhalation, before exhaling. 
After 6 s, the manoeuvre was repeated until the desired dose 
was delivered. At 2 min after the last inhalation, two FEV, 
values were recorded. Immediately after recording two 
FEV, values, the next dose was given. After the diluent had 
been inhaled, methacholine in cumulative doses from 
0.0039 mg to 2.0 mg was inhaled. Methacholine solutions 
in concentrations of 0.39 mg ml- ‘, 0.78 mg ml- I, 
1.56 mg ml-‘, 6.25 mg ml-’ and 12.50 mg ml-’ were 
used. The test was stopped when the subjects FEV, was 
reduced by 20% compared with the post-saline FEV, or at 
a cumulative dose of 2 mg of methacholine. If the post- 
diluent FEV, was reduced by more than 10% compared 
with the pre-diluent FEV,, the test was not performed. 
Methacholine. chloride U.S.P. XXI/NFXVI in buffered 
phosphate (pH 7~2-7.4) was used. The solutions used at all 
three centres were prepared by the hospital pharmacy in 
Ume& according to the recommendations of the ECRHS 
protocol. 
Definitions 
l PD,,. This is the cumulative dose of methacholine 
causing a 20% decline in FEV, compared with the 
post-diluent value. 
l BHR. The definition recommended by Balzano et al. (32) 
has been used; PD,, I 1.6 mg. When other limits of BHR 
have been used, this is noted. 
l Dose-response slope (DRS) of methacholine. This is 
the percentage decline in FEV, divided by the final 
cumulative dose of methacholine administered (33). 
Statistics 
Statistical analysis was performed using the Statistical Pack- 
age for Social Sciences (SPSS). The t-test and x2 test were 
used to test differences between groups; PcO.05 was re- 
garded as significant. When comparing differences in BHR 
between the three centres, an ANOVA test for trends was 
used. Multiple logistic regression was used to analyse the 
simultaneous influence of different determinants on BHR. 
TABLE 1. Prevalence of BHR by sex, area and smoking 
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Non-smoker Former smoker Smoker Total 
No. of 
MWTMWTMW T M W T participants 
Goteborg 5.7 15.2 10.1 11.9 7.3 9.7 10.1 19.6 15.4 8.5 15.4 11.9 538 
Uppsala 8.2 11.2 9.6 9.8 10.5 10.2 18.8 18.2 18.5 11.2 13.0 12.0 499 
Vasterbotten 1,4.4 11.7 13.2 9.8 17.5 12.9 11.1 25.0 19.1 12.4 17.0 14.6 411 
Total 9.2 12.7 102l 10.5 11.2 10.8 13.1 20.6 17,2** 10.6 15,0* 12.7 1448 
Significant difference between men and women (*P=O.Ol 1) and between smokers and never-smokers (**P<O.O05). 
M, men; W, women; T, total. 
When the association between DRS and various risk 
factors and symptoms was analysed, DRS was grouped into 
seven groups (~0, 0-~2, 2-~4, 4~6, 66~8, 88~20, 20+). 
Analyses were then performed, using a x2 test. To analyse 
the association with positive answers to the questions ‘Have 
you had an attack of shortness of breath that came on 
during the day when you were at rest at any time in the last 
12 months? and ‘Have you been woken by an attack of 
shortness of breath at any time in the last 12 months?’ the 
two groups <O and 0~2 were put together to avoid cells 
with expected frequency ~5. Multiple-regression analysis 
was used to examine the simultaneous effects of different 
determinants on the DRS. Since the distribution of DRS 
was positively skewed, 1ogDRS was used in the multiple 
regression. A constant of 10 was added to avoid negative 
DRS values. When comparing differences in DRS distribu- 
tion in the three centres, to minimize the effect of possible 
differences in the nebulizers used, ‘DRS’ was also calculated 
as percentage decline in FEV,/log(final cumulative dose of 
methacholine administered+ l), as has been recommended 
by Chinn et al. (34). 
cance (Table 1). The PD,, distribution in the three centres 
is shown in Fig. 2 (note that the intervals are uneven). 
BHR was associated with self-reported asthma (P<O.OOl), 
self-reported asthma in the last 12 months (P<O.OOl) and 
self-reported rhinoconjunctivitis (P<O.OOl). The sensitivity 
for BHR concerning self-reported asthma was 48% and the 
specificity was 90% (Table 2). The positive predictive value 
was 28% and the negative predictive value was 96%. 
BHR was associated with the prevalence of reported 
symptoms in the last 12 months of wheezing (P<O.OOl), 
being awakened by tightness in the chest (P<O.OOl), attacks 
of shortness of breath at rest during the daytime (P<O.OOl), 
attacks of shortness of breath after strenuous activity 
(P<O.OOl) or being awakened by shortness of breath 
(P<O.OOl). In subjects with BHR, all these symptoms were 
significantly more common in subjects with self-reported 
asthma than in those without self-reported asthma in all 
three areas (Table 3). 
Results 
In the logistic regression analysis, using BHR as a 
dependent variable, atopy, being female, having a low 
FEV, (% predicted) and smoking increased the odds of 
BHR by 3.0, 1.9, 2.8 and 2.2 respectively (Table 4). Using 
non-smokers as the reference, passive smoking increased 
In all, 1448 subjects (748 men, 700 women) participated in 
the methacholine challenge test. The response rates in 
Giiteborg, Uppsala and Vbterbotten were 79%, 80% and 
75% respectively (Fig. 1). When participants were com- 
pared with non-participants using the answers from the 
screening questionnaire, there were no differences in terms 
of the prevalence of self-reported smoking or asthma 
attacks. The prevalence of self-reported wheezing was 
higher among participants compared with non-participants, 
predominantly in Vasterbotten. Non-participants had a 
slightly lower mean age. 
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FIG. 2. Distribution of subjects with measurable PD, in 
The prevalence of BHR was 12,7%, 10.6% in men and the three areas as percentages of participants in each area 
15.0% in women. BHR was more prevalent in women than [n=64/538 in Goteborg, (m), n=60/499 in Uppsala @) 
in men (P<O.Oll) and more prevalent in smokers than in and n = 591411 in Umea (El). Note that the intervals are 
non-smokers (P<O.O02). There was a tendency towards a uneven. Also note that 88.1% in Giiteborg, 88% in 
higher prevalence of BHR in Vasterbotten than in the other Uppsala and 85.4% in Vasterbotten did not have any 
centres, but the difference did not reach statistical signifi- measurable PD,,. 
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TABLE 2. Prevalence of BHR in subjects with and without self-reported asthma and self-reported 
asthma in last 12 months 
Self-reported asthma Self-reported asthma in last 12 months 
Yes No Yes No 
BHR n % n % n % n % 
Yes 52 48 132 10 41 65 143 10 
No 56 52 1207 90 22 35 1240 90 
Total 108 100 1339 100 63 100 1383 100 
TABLE 3. Prevalence (%) of positive answers to questions about symptoms in subjects with BHR by self-reported asthma 
(n = 52) and no self-reported asthma (n = 13 1) 
Question: Have you . . at any 
time in the last 12 months? 
Giiteborg Uppsala Viisterbotten Total 
SA No SA SA No SA SA No SA SA No SA 
Had wheezing or whistling in chest your 
Woken with a feeling of tightness in chest up your 
Had an attack of shortness of breath that came on 
during the day when you were at rest 
Had an attack of shortness of breath that came on 
following strenuous activity 
Been woken by an attack of shortness of breath 
88 5.5 80 47 75 33 81 46 
77 17 40 18 40 5.1 52 14 
41 11 33 0 20 2.6 31 4.6 
59 6.4 60 16 55 5.1 58 9.2 
35 4.3 33 4.4 15 0 27 3.1 
Self-reported asthma, SA, no self-reported asthma, No SA. 
the risk by 3.2. Age and living in any of the areas did not 
increase the risk. using alternative definitions of BHR did 
not affect the results (Table 4); neither did changing the 
definition of atopy into ‘any reaction greater than negative 
control’. 
As the relationship between self-reported asthma and 
BHR is strong, an analysis was performed separately on 
subjects with and without self-reported asthma. In this 
setting, smoking and being female did not increase the risk 
in subjects with self-reported asthma; otherwise the results 
remained the same. 
DOSE-RESPONSE SLOPE 
The distribution of DRS in the three areas is shown in 
Fig. 3 and Table 5. There was a significant difference in the 
mean 1ogDRS between the three areas (P=O.O3), that 
disappeared when smokers were excluded. In never- 
smokers there was no significant difference between the 
areas. However, there was a significant trend (PcO.04) 
towards higher log DRS in the northerly areas, but this was 
only caused by non-smoking men. 
DRS was associated with atopy and FEV, (% predicted) 
in both men and women (P<O.OOl). Self-reported asthma 
(P<O*OOl) and self-reported rhinoconjunctivitis (P<O.OOl) 
were associated with DRS at all the centres and in both men 
and women, smokers and non-smokers. Smoking (Table 5 
was significantly associated with DRS (P<O.OOl). 
Reporting symptoms of wheezing (P<O.OOl), being 
awakened by tightness in the chest (P<O.OOl), attacks of 
shortness of breath at rest during the daytime (P<O.OOl), 
attacks of shortness of breath after strenuous activity 
(P<O.OOl) or being awakened by shortness of breath 
(P<O.OOl) during the last 12 months were all associated 
with DRS. 
In multiple regression, using log DRS as the dependent 
variable and atopy, FEV, (% predicted), sex, living area, 
smoking and age as independent variables, being female 
(P<O.OOl), atopic (P<O.OOl), smoker (PcO.02) or having a 
low FEV, (% predicted) (P<O*OOl) were included in the 
model (R’=O.ll). 
Discussion 
In this study we found a prevalence of BHR of 12.7%, using 
the definition recommended by Balzano et al. An analysis 
of the non-responders revealed only minor differences 
between participants and non-participants, indicating that 
the prevalence reflects the ‘true’ prevalence in the investi- 
gated population. There was a trend towards a higher 
prevalence of BHR in the most northerly of the study areas, 
but the difference was only statistically significant, and in 
fact only visible, in non-smoking men. In the initial postal 
questionnaire, no difference in the prevalence of self- 
reported asthma was seen between the three centres. These 
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TABLE 4. Logistic regression analysis of BHR by atopy, age, sex, area and smoking 
Dependent variable = BHR 
Independent 
variables Categories 
PD,, 2 1 mg PD,, 5 1.6 mg PD,, < 2 mg 
OR 95% CI OR 95% CI OR 95% CI 
AtOm 
Sex 
Smoking 
Area 
Age 
FEV, (% predicted) 
No 1 
Yes 3.43 
Male 1 
Female 1.85 
Non-smoker, no passive smoking 1 
Non-smoker, passive smoking 3.67 
Ex-smoker, no passive smoking 1.68 
Ex-smoker, passive smoking 2.71 
Smoker 2.11 
Goteborg 1 
Uppsala 0.73 
Vasterbotten 1.44 
20-24 years 1 
25-29 years 1.02 
30-34 years 0.64 
35-39 years 0.58 
40+ years 0.85 
90-cl10 1 
<90 3.04 
llO-Cl30 0.29 
3130 0.11 
2.30-5.09 
1.2552.77 
1.747.75 
0.93-3.04 
0.93-7.90 
1.31-3.40 
0.44-1.20 
0.81-2.57 
0.60-l .72 
0.37-1.11 
0.23-1.50 
0.36-2.01 
1.72-5.37 
0.18-0.49 
0.01-0.80 
1 1 
3.00 2.144.20 2.67 
1 1 
1.91 1.362.69 2.03 
1 1 
3.23 1.70-6.13 2.49 
1.41 0.85-2.34 1.38 
1.73 0.6664.52 1.43 
2.16 1443.22 2.05 
1 1 
0.95 0.63-l .45 1.18 
1.22 0.72-2.07 1.48 
1 1 
1.15 0.73-1.83 1.02 
0.68 0.42-1.10 0.80 
0.97 0.43-2.15 0.95 
1.58 0.77-3.29 1.53 
1 1 
2.79 1.644.76 2.38 
0.51 0.35-0.75 0.47 
0.16 0~04-0~70 0.12 
1.96-3.65 
1.48-2.79 
1.354.60 
0.87-2.21 
0.58-3.51 
14-2.98 
0.80-1.74 
0.91-2.40 
0.66-1.56 
0.52-l .24 
0.462.00 
0.7883.00 
1.4333.99 
0.34-0.67 
0.03-0.50 
OR, odds ratio; CI, confidence interval. 
findings do not support the theory of a higher prevalence of 
asthma in the northern part of Sweden compared with the 
southern part. 
The fact that both Uppsala and Umea are university 
towns and Goteborg-Hisingen is inhabited by a large 
number of immigrants might weaken the possibility of 
detecting any difference caused by slow-acting agents or 
heredity-isolation factors, because of large-scale movements 
in the population. Since subjects with wheezing tended to 
participate to a greater extent in Visterbotten than in 
Uppsala and Giiteborg, selection bias does not explain the 
lack of difference. 
The trend towards increased reactivity in the north was 
caused predominantly by non-smoking men. In non- 
smoking women, no such trend was seen. Since BHR has 
8 
30 
25 
8 20 
‘-2 
& 
15 
E 10 5 
0 
<o o-<2 2%<4 P<6 6-4 a-c20 20<50 50 + 
DRS 
BHR was more common in smokers than in non- 
smokers. The finding that at least male non-smokers 
exposed to passive smoking also ran a higher risk of BHR 
indicates that cigarette smoke is a strong inducer of BHR. 
Although the differences were not significant in former 
smokers, the risk of BHR was 1.4 compared with non- 
smokers, but it increased to 1.7 in former smokers exposed 
to passive smoking. In the present study, the increased 
risk in smokers was not explained by a lower FEV, (% 
predicted). 
FIG. 3. Distribution of DRS values in the three areas A low FEV, (% predicted) increased the risk of BHR, as 
(n= 1448): n , Giiteborg; 69, Uppsala; 0, Vasterbotten. has previously been reported (8810,22). As in other studies, 
been shown to be common in subjects performing extremely 
strenuous activities in cold air (28) one explanation might 
be that men are exposed to cold air during physically hard 
work or exercise more frequently than women. 
BHR was more common in women than in men. In a 
recent study from New Zealand, BHR was shown to be 
more common in boys than in girls at the age of 9 years, but 
this difference disappeared at the age of 15 years (12). The 
bronchial reactivity of boys appeared to normalize with 
age to a higher extent than that of girls. Studies from the 
northern part of Sweden have revealed a higher prevalence 
of asthma in young women than in men (3,5,35). The 
diameter of the airways has been discussed as a possible 
explanation of the observed gender difference (8-10,26). In 
this study, the gender difference remained when FEV, (% 
predicted) was included in the model. 
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TABLE 5. DRS, median and range by sex, study area and smoking habits 
Men Women Total 
Median Range Median Range Median Range 
Study area 
Giiteborg 
Uppsala 
Vbterbotten 
Smoking habits 
Non-smoker 
Ex-smoker 
Smoker 
2.9 - 19.4 to 1313 4.2 - 2.0 to 760 3.4 - 19.4 to 1313 
2.6 - 5.3 to 844 3.2 - 3.5 to 2704 3.0 - 5.3 to 2704 
3.8 - 5.2 to 456 4.7 - 3.5 to 1570 4.2 - 5.2 to 1570 
3.0 - 19.4 to 371 3.3 - 3.5 to 1583 3.1 - 19.4 to 1583 
3.0 -5.3 to 1313 3.8 - 3.5 to 2704 3.2 - 5.3 to 2704 
3.2 - 5.2 to 844 5.0 - 1.7 to 434 4.2 - 5.2 to 844 
Total 3.4 - 19.3 to 1313 4.2 - 3.5 to 2704 3.4 - 19.3 to 2704 
atopy was positively associated with DRS and increased the analysis. This study has been made possible by grants from 
risk of BHR. Self-reported rhinoconjuctivitis was also the Swedish Heart and Lung Foundation, the Swedish 
significantly associated with DRS and BHR (8,36). These Association against Asthma and Allergy, the Swedish 
findings indicate that the formation of IgE antibodies and Medical Research Council, the Associations against 
exposure to allergens in sensitized individuals increase Asthma and Allergy in Giiteborg, Uppsala and the north- 
bronchial responsiveness and are in agreement with studies em regions, the Herman Krefting Foundation, the Bror 
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